Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation

Koay, Eugene J.; Zaid, Mohamed; Aliru, Maureen; Bagereka, Polycarpe; Wieren, Arie Van; Rodriguez, Megan; Jacobson, Galia; Wolff, Robert A.; Overman, Michael J.; Varadhachary, Gauri R.; Pant, Shubham; Wang, Huamin; Tzeng, Ching‐Wei D.; Ikoma, Naruhiko; Kim, Michael; Lee, Jeffrey E.; Katz, Matthew H.G.; Tamm, Eric P.; Bhosale, Priya; Taniguchi, Cullen M.; Holliday, Emma B.; Smith, Grace L.; Ludmir, Ethan B.; Minsky, Bruce D.; Crane, Christopher H.; Koong, Albert C.; Das, Prajnan; Wang, Xuemei; Javle, Milind; Krishnan, Sunil

doi:10.1016/j.ijrobp.2022.06.089

Cited by 6 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A more defined tumor interface response (IR) was associated with better survival outcomes. These promising results therefore support the development of further trials and suggest IR could be a meaningful biomarker [94].…”

Section: Conclusion and Future Perspectivessupporting

confidence: 61%

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian

Cortiana,

Abbas,

Chorya

et al. 2024

Cancers

View full text Add to dashboard Cite

Pancreatic cancer, with its alarming rising incidence, is predicted to become the second deadliest type of solid tumor by 2040, highlighting the urgent need for improved diagnostic and treatment strategies. Despite medical advancements, the five-year survival rate for pancreatic cancer remains about 14%, dropping further when metastasized. This review explores the promise of biomarkers for early detection, personalized treatment, and disease monitoring. Molecular classification of pancreatic cancer into subtypes based on genetic mutations, gene expression, and protein markers guides treatment decisions, potentially improving outcomes. A plethora of clinical trials investigating different strategies are currently ongoing. Targeted therapies, among which those against CLAUDIN 18.2 and inhibitors of Claudin 18.1, have shown promise. Next-generation sequencing (NGS) has emerged as a powerful tool for the comprehensive genomic analysis of pancreatic tumors, revealing unique genetic alterations that drive cancer progression. This allows oncologists to tailor therapies to target specific molecular abnormalities. However, challenges remain, including limited awareness and uptake of biomarker-guided therapies. Continued research into the molecular mechanisms of pancreatic cancer is essential for developing more effective treatments and improving patient survival rates.

show abstract

Section: Conclusion and Future Perspectivessupporting

confidence: 61%

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian

Cortiana,

Abbas,

Chorya

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…These preclinical findings demonstrated that this novel paclitaxel will be thus a good candidate for testing in clinical chemoradiotherapy trials. To the best of our knowledge, there have been several trials regarding nab-paclitaxel for different cancer types, such as melanoma, head and neck cancer, pancreatic cancer, and ovarian cancer, among others (Oppelt et al 2021 and Koay et al 2022 ; Li et al 2022 ; Colombo et al 2023 ). It was demonstrated that nab-paclitaxel cross endothelial cell monolayers and enter tumors through endogenous albumin transport pathways, including receptor-mediated transcytosis (Desai et al 2006 and Desai et al 2009 ).…”

Section: Discussionmentioning

confidence: 99%

Evaluating the clinical efficacy and safety of concurrent chemoradiotherapy with cisplatin and nab-paclitaxel in postoperative early-stage cervical cancer

Zhao,

Li,

Chen

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Objective A preclinical study showed that nab-paclitaxel acted as a radiosensitizer and improved tumor radiotherapy in a supra-additive manner. In this study, we aimed to evaluate the clinical efficacy and safety of concurrent chemoradiotherapy (CCRT) with cisplatin and nab-paclitaxel in postoperative early-stage cervical cancer with an unfavorable prognosis. Methods Eligible patients with stage IB1-IIA2 (FIGO 2009) cervical carcinoma were recruited retrospectively between August 2018 to May 2021. Patients in both the cisplatin and nab-paclitaxel groups received postoperative radiotherapy and weekly intravenous cisplatin 40 mg/m2 or nab-paclitaxel 100 mg concurrently. An analysis of overall survival, progression-free survival, and adverse reactions was conducted. Results A total of 105 early-stage cervical cancer patients were included into our study. The median follow-up time was 38.7 months. The 3-year overall survival and progression-free survival in both group was similar. The cycles of chemotherapy in the cisplatin group were less than those in the nab-paclitaxel group (4.5 vs. 5.0; p = 0.001). Patients in the cisplatin group had a significantly higher frequency of hematological adverse events than patients in the nab-paclitaxel group (P < 0.05). Patients in the cisplatin group had a significantly higher frequency of grade 3–4 leukopenia (46.1% vs. 18.9%; P = 0.03), grade 1–2 thrombocytopenia (32.7% vs. 9.5%; P = 0.014) than patients in the nab-paclitaxel group. Gastrointestinal reactions, such as vomiting, nausea, and anorexia were significantly reduced in the nab-paclitaxel group compared with those in the cisplatin group. Regarding the effects on alopecia, the incidence rate of the nab-paclitaxel group was higher than that of the cisplatin group (P = 0.001). There were no differences between the groups in terms of other adverse reactions. Conclusion The results of this study indicate that nab-paclitaxel-based concurrent radiotherapy is tolerable and effective, and can be considered an alternative to cisplatin chemotherapy.

show abstract

“…Subsequently, patients at low risk and those who do not qualify for TORS (due to volume of disease or poor visualization/access) or refuse TORS will be administered de-intensified treatment with radiation alone at 50 Gy. Next, an Abraxane Phase I trial (NCT02394535) was initiated to treat advanced pancreatic cancer patients with combined RT assisted by Abraxane and apecitabine orally twice daily on days 1–5 [ 38 ]. The initial efficacy results of concurrent Abraxane with capecitabine RT are promising; however, the Phase II trial (NCT01921751) was terminated because of an unreasonable timeframe [ 37 ].…”

Section: Clinical Trials Involving the Translation Of Nanotechnology ...mentioning

confidence: 99%

Recent Advances in Metal-Based NanoEnhancers for Particle Therapy

Chuang

Shen

et al. 2023

Nanomaterials

View full text Add to dashboard Cite

Radiotherapy is one of the most common therapeutic regimens for cancer treatment. Over the past decade, proton therapy (PT) has emerged as an advanced type of radiotherapy (RT) that uses proton beams instead of conventional photon RT. Both PT and carbon-ion beam therapy (CIBT) exhibit excellent therapeutic results because of the physical characteristics of the resulting Bragg peaks, which has been exploited for cancer treatment in medical centers worldwide. Although particle therapies show significant advantages to photon RT by minimizing the radiation damage to normal tissue after the tumors, they still cause damage to normal tissue before the tumor. Since the physical mechanisms are different from particle therapy and photon RT, efforts have been made to ameliorate these effects by combining nanomaterials and particle therapies to improve tumor targeting by concentrating the radiation effects. Metallic nanoparticles (MNPs) exhibit many unique properties, such as strong X-ray absorption cross-sections and catalytic activity, and they are considered nano-radioenhancers (NREs) for RT. In this review, we systematically summarize the putative mechanisms involved in NRE-induced radioenhancement in particle therapy and the experimental results in in vitro and in vivo models. We also discuss the potential of translating preclinical metal-based NP-enhanced particle therapy studies into clinical practice using examples of several metal-based NREs, such as SPION, Abraxane, AGuIX, and NBTXR3. Furthermore, the future challenges and development of NREs for PT are presented for clinical translation. Finally, we propose a roadmap to pursue future studies to strengthen the interplay of particle therapy and nanomedicine.

show abstract

Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation

Cited by 6 publications

References 43 publications

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian

Evaluating the clinical efficacy and safety of concurrent chemoradiotherapy with cisplatin and nab-paclitaxel in postoperative early-stage cervical cancer

Recent Advances in Metal-Based NanoEnhancers for Particle Therapy

Contact Info

Product

Resources

About